SVN53-67/M57-KLH Peptide Vaccine

BIOLOGICAL5 trials

Conditions

Digestive System Neuroendocrine NeoplasmGlioblastomaGliosarcomaLung Atypical Carcinoid TumorLung CarcinomaLung Neuroendocrine NeoplasmLung Typical Carcinoid TumorMalignant Solid Neoplasm

Phase 1

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Active, not recruitingNCT02334865

Roswell Park Cancer InstitutePartial Response of Multiple Myeloma or Plasma Cell Leukemia, Plasma Cell Myeloma

Start: 2017-04-13End: 2026-05-19Updated: 2025-05-11

Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors

CompletedNCT03879694

Roswell Park Cancer InstituteLung Atypical Carcinoid Tumor, Lung Typical Carcinoid Tumor, Metastatic Pancreatic Neuroendocrine Tumor

Start: 2019-06-17End: 2025-03-14Updated: 2026-02-06

Phase 2

SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Active, not recruitingNCT02455557

Roswell Park Cancer InstituteGlioblastoma, Gliosarcoma

Start: 2015-05-04End: 2026-06-02Updated: 2026-03-30

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

RecruitingNCT06202066

Roswell Park Cancer InstituteDigestive System Neuroendocrine Neoplasm, Lung Neuroendocrine Neoplasm, Malignant Solid Neoplasm +1

Start: 2026-04-15End: 2028-10-15Target: 60Updated: 2026-03-11

Testing the SurVaxM Vaccine for Lung Cancer Prevention

Not yet recruitingNCT07169617

National Cancer Institute (NCI)Lung Carcinoma

Start: 2026-02-25End: 2027-09-30Target: 80Updated: 2026-03-30

2025-10-09

RTID-04. A MULTICENTER, RANDOMIZED, CONTROLLED PHASE 2B TRIAL OF SURVIVIN VACCINE SURVAXM PLUS ADJUVANT TEMOZOLOMIDE FOR NEWLY-DIAGNOSED GLIOBLASTOMA (SURVIVE)

Neuro-Oncology2024-11-01

A multicenter, randomized controlled phase 2b trial of survivin vaccine SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma (SURVIVE).

Journal of Clinical Oncology2024-06-014 citations

P07.09.B A RANDOMIZED PHASE 2B STUDY OF SURVIVIN VACCINE SURVAXM PLUS ADJUVANT TEMOZOLOMIDE FOR NEWLY-DIAGNOSED GLIOBLASTOMA (SURVIVE)

Neuro-Oncology2023-09-012 citations

Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma

Journal of Clinical Oncology2022-12-15139 citations

CTIM-26. PHASE II TRIAL OF SURVAXM PLUS TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA

Neuro-Oncology2022-11-01

Final data from the phase 2a single-arm trial of SurVaxM for newly diagnosed glioblastoma.

Journal of Clinical Oncology2022-06-016 citations

SurVaxM with standard therapy in newly diagnosed glioblastoma: Phase II trial update.

Journal of Clinical Oncology2019-05-2017 citations

Phase II trial of SurVaxM combined with standard therapy in patients with newly diagnosed glioblastoma.

Journal of Clinical Oncology2018-05-203 citations

SVN53-67/M57-KLH Peptide Vaccine

Sponsors

Conditions

Phase 1

Phase 2

Related Papers